Paget’s Disease News and Research

RSS
X-rays help predict permanent bone damage from bisphosphonates

X-rays help predict permanent bone damage from bisphosphonates

Genta Incorporated issued two key U.S. patents for gallium products franchise

Genta Incorporated issued two key U.S. patents for gallium products franchise

Sun Pharmaceutical receives FDA approvals for 4 generics

Sun Pharmaceutical receives FDA approvals for 4 generics

Genta announces initial trial results for novel drug for bone disease

Genta announces initial trial results for novel drug for bone disease

Alendronate may improve successful implantation of maxillary bone

Alendronate may improve successful implantation of maxillary bone

Once a year treatment for osteoporosis now available in the U.S.

Once a year treatment for osteoporosis now available in the U.S.

Genta and Emisphere Technologies file investigational new drug exemption

Genta and Emisphere Technologies file investigational new drug exemption

Reclast found to cause abnormal heart rhythms

Reclast found to cause abnormal heart rhythms

Osteonecrosis of the jawbone and oral bisphosphonates

Osteonecrosis of the jawbone and oral bisphosphonates

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

Early patient response to Forteo in postmenopausal women with osteoporosis

Early patient response to Forteo in postmenopausal women with osteoporosis

First filing for zoledronic acid in metabolic bone disease

First filing for zoledronic acid in metabolic bone disease